Genome editing provides new insights into receptor-controlled signalling pathways

Milligan, G. and Inoue, A. (2018) Genome editing provides new insights into receptor-controlled signalling pathways. Trends in Pharmacological Sciences, 39(5), pp. 481-493. (doi: 10.1016/j.tips.2018.02.005) (PMID:29548548)

[img]
Preview
Text
157021.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

2MB

Abstract

Rapid developments in genome editing, based largely on CRISPR/Cas9 technologies, are offering unprecedented opportunities to eliminate the expression of single or multiple gene products in intact organisms and in model cell systems. Elimination of individual G protein-coupled receptors (GPCRs), both single and multiple G protein subunits, and arrestin adaptor proteins is providing new and sometimes unanticipated insights into molecular details of the regulation of cell signalling pathways and the behaviour of receptor ligands. Genome editing is certain to become a central component of therapeutic target validation, and will provide pharmacologists with new understanding of the complexities of action of novel and previously studied ligands, as well as of the transmission of signals from individual cell-surface receptors to intracellular signalling cascades.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Milligan, Professor Graeme
Authors: Milligan, G., and Inoue, A.
College/School:College of Medical Veterinary and Life Sciences > Institute of Molecular Cell and Systems Biology
Journal Name:Trends in Pharmacological Sciences
Publisher:Elsevier
ISSN:0165-6147
ISSN (Online):1873-3735
Published Online:13 March 2018
Copyright Holders:Copyright © 2018 Elsevier Ltd.
First Published:First published in Trends in Pharmacological Sciences 39(5): 481-493
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
659371Designer Receptor Exclusively Activated by Designer Drug' to define the role of short chain fatty acids in metabolic disease and inflammation (Fatty acid DREADD)Graeme MilliganBiotechnology and Biological Sciences Research Council (BBSRC)BB/L027887/1RI MOLECULAR CELL & SYSTEMS BIOLOGY
618921GPR120: a G protein-coupled receptor with the potential to regulate insulin secretion and inflammationGraeme MilliganBiotechnology and Biological Sciences Research Council (BBSRC)BB/K019864/1RI MOLECULAR CELL & SYSTEMS BIOLOGY